258 related articles for article (PubMed ID: 22834478)
1. In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective β3-adrenoceptor agonist.
Takusagawa S; Miyashita A; Iwatsubo T; Usui T
Xenobiotica; 2012 Dec; 42(12):1187-96. PubMed ID: 22834478
[TBL] [Abstract][Full Text] [Related]
2. Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β3-adrenoceptor agonist.
Takusagawa S; Yajima K; Miyashita A; Uehara S; Iwatsubo T; Usui T
Xenobiotica; 2012 Oct; 42(10):957-67. PubMed ID: 22509825
[TBL] [Abstract][Full Text] [Related]
3. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.
Sahi J; Black CB; Hamilton GA; Zheng X; Jolley S; Rose KA; Gilbert D; LeCluyse EL; Sinz MW
Drug Metab Dispos; 2003 Apr; 31(4):439-46. PubMed ID: 12642470
[TBL] [Abstract][Full Text] [Related]
4. In vitro assessment of cytochrome P450 inhibition and induction potential of felotaxel (SHR110008).
Ding Y; Jia Y; Lu C; Liu W; Yang J; Song Y; Zhu Y; Yang L; Ding L; Wen A
Biomed Pharmacother; 2012 Jun; 66(4):318-21. PubMed ID: 22397757
[TBL] [Abstract][Full Text] [Related]
5. An in vitro evaluation of the victim and perpetrator potential of the anticancer agent laromustine (VNP40101M), based on reaction phenotyping and inhibition and induction of cytochrome P450 enzymes.
Nassar AE; King I; Paris BL; Haupt L; Ndikum-Moffor F; Campbell R; Usuki E; Skibbe J; Brobst D; Ogilvie BW; Parkinson A
Drug Metab Dispos; 2009 Sep; 37(9):1922-30. PubMed ID: 19520774
[TBL] [Abstract][Full Text] [Related]
6. In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil.
Robertson P; DeCory HH; Madan A; Parkinson A
Drug Metab Dispos; 2000 Jun; 28(6):664-71. PubMed ID: 10820139
[TBL] [Abstract][Full Text] [Related]
7. Mirabegron, a β₃-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder.
Tyagi P; Tyagi V
IDrugs; 2010 Oct; 13(10):713-22. PubMed ID: 20878594
[TBL] [Abstract][Full Text] [Related]
8. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes.
Parkinson A; Mudra DR; Johnson C; Dwyer A; Carroll KM
Toxicol Appl Pharmacol; 2004 Sep; 199(3):193-209. PubMed ID: 15364537
[TBL] [Abstract][Full Text] [Related]
9. In vitro studies investigating the interactions between degarelix, a decapeptide gonadotropin-releasing hormone blocker, and cytochrome P450.
Sonesson A; Rasmussen BB
Basic Clin Pharmacol Toxicol; 2011 Sep; 109(3):195-202. PubMed ID: 21496210
[TBL] [Abstract][Full Text] [Related]
10. In vitro assessment of cytochrome P450 inhibition and induction potential of tanespimycin and its major metabolite, 17-amino-17-demethoxygeldanamycin.
Gan J; Liu-Kreyche P; Humphreys WG
Cancer Chemother Pharmacol; 2012 Jan; 69(1):51-6. PubMed ID: 21594721
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes.
McGinnity DF; Berry AJ; Kenny JR; Grime K; Riley RJ
Drug Metab Dispos; 2006 Aug; 34(8):1291-300. PubMed ID: 16679385
[TBL] [Abstract][Full Text] [Related]
12. Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81.
Zhang JG; Dehal SS; Ho T; Johnson J; Chandler C; Blanchard AP; Clark RJ; Crespi CL; Stresser DM; Wong J
Drug Metab Dispos; 2006 May; 34(5):734-7. PubMed ID: 16501008
[TBL] [Abstract][Full Text] [Related]
13. In vitro characterization of the metabolic pathways and cytochrome P450 inhibition and induction potential of BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor.
Hong H; Su H; Ma L; Yao M; Iyer RA; Humphreys WG; Christopher LJ
Drug Metab Dispos; 2011 Sep; 39(9):1658-67. PubMed ID: 21673131
[TBL] [Abstract][Full Text] [Related]
14. In vitro inhibition and induction of human liver cytochrome p450 enzymes by milnacipran.
Paris BL; Ogilvie BW; Scheinkoenig JA; Ndikum-Moffor F; Gibson R; Parkinson A
Drug Metab Dispos; 2009 Oct; 37(10):2045-54. PubMed ID: 19608694
[TBL] [Abstract][Full Text] [Related]
15. Direct and metabolism-dependent cytochrome P450 inhibition assays for evaluating drug-drug interactions.
Lee KS; Kim SK
J Appl Toxicol; 2013 Feb; 33(2):100-8. PubMed ID: 21915887
[TBL] [Abstract][Full Text] [Related]
16. Inhibition and induction of human cytochrome P450 enzymes in vitro by capsaicin.
Babbar S; Chanda S; Bley K
Xenobiotica; 2010 Dec; 40(12):807-16. PubMed ID: 20863199
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes.
Xing J; Kirby BJ; Whittington D; Wan Y; Goodlett DR
Drug Metab Dispos; 2012 Sep; 40(9):1757-64. PubMed ID: 22679214
[TBL] [Abstract][Full Text] [Related]
18. In vitro evaluation of the interaction potential of irosustat with drug-metabolizing enzymes.
Ventura V; Solà J; Peraire C; Brée F; Obach R
Drug Metab Dispos; 2012 Jul; 40(7):1268-78. PubMed ID: 22451700
[TBL] [Abstract][Full Text] [Related]
19. In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics.
Zhou D; Andersson TB; Grimm SW
Drug Metab Dispos; 2011 Apr; 39(4):703-10. PubMed ID: 21177984
[TBL] [Abstract][Full Text] [Related]
20. Follow-up to the pre-validation of a harmonised protocol for assessment of CYP induction responses in freshly isolated and cryopreserved human hepatocytes with respect to culture format, treatment, positive reference inducers and incubation conditions.
Abadie-Viollon C; Martin H; Blanchard N; Pekthong D; Bachellier P; Mantion G; Heyd B; Schuler F; Coassolo P; Alexandre E; Richert L
Toxicol In Vitro; 2010 Feb; 24(1):346-56. PubMed ID: 19497360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
